Shineco, Plus Me partner on blockchain-based cellular asset tokenization.

Shineco Inc., a leading innovator in induced pluripotent stem cell technology, has partnered with blockchain infrastructure provider Plus Me Limited to enable blockchain-based tokenization of biological cellular assets. This collaboration will facilitate global transfers and auditable standardized custody, creating a new model for the cell therapy industry. Under the agreement, Plus Me will deploy full lifecycle digital custody of Shineco's compliant MSCs on the Ethereum mainnet, securing asset ownership rights and issuing unique NFDIs for each cellular asset.

Shineco Inc., a leading innovator in induced pluripotent stem cell (iPSC) technology, has partnered with blockchain infrastructure provider Plus Me Limited to enable blockchain-based tokenization of biological cellular assets. This collaboration will facilitate global transfers and auditable standardized custody, creating a new model for the cell therapy industry. Under the agreement, Plus Me will deploy full lifecycle digital custody of Shineco's compliant mesenchymal stem cells (MSCs) on the Ethereum mainnet, securing asset ownership rights and issuing unique non-fungible digital identifiers (NFDIs) for each cellular asset [1].

The partnership aims to address critical industry pain points, such as high user costs, unverifiable product provenance, and illiquid asset pools, by converting biological assets into tradable digital instruments. Plus Me will issue ERC-1400/ERC-20 compliant security tokens, branded as "Cell Infusion Redemption Tokens," which can be redeemed at Shineco-affiliated Cell Therapy Centers. These tokens are programmatically burned upon redemption, enforcing scarcity and aligning long-term value for stakeholders.

To bolster the initiative, Shineco has secured a controlling 51% stake in Xi'an Dong'ao Health Management Co., Ltd., a specialist in cryogenic cell storage and clinical applications. This strategic buyout provides the off-chain infrastructure critical to token redemption and complements previously acquired Singapore firm Infiniclone, ensuring a global storage and infusion network for on-chainoff-chain asset settlement.

The collaboration will also co-build an open-cell industry ecosystem, with Plus Me providing tokenization SaaS to third parties and Shineco opening its physical custody network. Shineco maintains off-chain biological quality assurance (QA), while Plus Me ensures on-chain regulatory compliance, creating cross-jurisdictional synergy with entities like Singapore's ACTRIS.

Shineco's asset tokenization protocol aligns with the industry's shift from clinical trials to commercial scalability. "This marks the birth of a decentralized biotech economy—where every cell becomes a liquid, programmable asset, unlocking unprecedented value for medicine and investors alike," said Jennifer Zhan, CEO of Shineco. Token holders will gain governance rights, including future DAO voting to enhance global ecosystem development in cell therapy—fundamentally transforming traditional marketing paradigms.

References:
[1] https://www.prnewswire.com/news-releases/shineco-unveils-worlds-first-on-chain-cell-asset-tokenization-platform-strategic-acquisition-expands-global-blockchain-biotech-network-302534286.html